Mammography Market Size, Share & Trends Analysis Report By Product (Film Screen, Digital, Analog, Biopsy Systems, 3D Systems), By Technology (Breast Tomosynthesis, CAD, Digital), By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global mammography market size was valued at USD 1.9 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 10.3% from 2022 to 2030. The rising prevalence of breast cancer and increasing demand for early-stage diagnosis among patients are some of the key factors anticipated to drive demand for breast cancer diagnostic devices during the forecast period. Increased access to breast cancer screening systems and growing government initiatives to support clinical interpretation are some of the pivotal factors expected to propel the market growth.

The market is expected to witness significant growth due to various breast cancer diagnosis initiatives. For instance:

• The Health Resources and Services Administration (HRSA) had introduced a healthcare program to increase the screening procedures in medically underserved areas

• BreastScreen Australia is a collaborative initiative of the Australian and state and territory governments that aims to reduce breast cancer illness and death by detecting the disease early. Women over the age of 40 are eligible for a free mammography every two years, and women aged 50 to 74 are actively encouraged to screen

• In October 2021, the government of Goa, India launched an initiative for free breast cancer screening for 1 lakh women. Breast cancer screening will be carried out at 35 Health Centres across Goa as part of this campaign

The COVID-19 pandemic resulted in significant reductions in cancer screening, cancer management visits, and cancer procedures across the globe. According to a study in the Journal of the American College of Radiology, at the peak of the pandemic in 2020, mammograms dropped to a dramatic low, reducing by up to 92% in some areas in the U.S. According to the FDA, the number of women examined for breast cancer in 2021 was 38.8 million, implying that hundreds of thousands of women in the U.S. may have missed or delayed screenings owing to the pandemic. This decline in screening volume caused by the COVID-19 has presented radiologists with additional challenges.

The repercussions of delayed cancer detection owing to COVID-19 were investigated in a study undertaken in the U.K. and published in the Lancet Oncology in March 2021. The study covered data from over 100,000 people with breast, colorectal, esophageal, or lung cancer. The study found that 1 and 5-year cancer survival rates will be severely reduced because of the outbreak of COVID-19, owing to the lack of availability of screening services. As a result, owing to lockdowns, screening services were disrupted to some extent which lowered the demand for mammography systems. This negatively impacted the mammography market.

However, numerous physician reports from the U.S. have observed a growing number of screening appointments during the last quarter of 2020 which is expected to continually rise to reach pre-covid levels by the latter half of 2021. In addition, adoption of AI technologies on a larger scale, clinicians will be able to manage their workload more effectively and with more precision, potentially reducing inequities in patient care. The number of screening mammograms is expected to witness an increasing trend post-pandemic. This will positively contribute to the market growth in the coming years.

The increasing incidence of breast cancer across the globe is one of the major factors responsible for the growth of the mammography market. For instance, according to a Globocan report from 2020, breast cancer was the most common type of cancer, with a prevalence rate of 11.7%. According to the same survey, the five-year estimated prevalence for both sexes indicated that Asia had the highest number of persons affected at 3,218,496 (41.3%), followed by Europe at 2,138,117 (27.4%), and North America with 1.189,111 people (15.3%).

Moreover, according to the WHO, in 2018, around 627,000 women died due to breast cancer 2018 globally, and it is also estimated that the rate of breast cancer is higher among women in developed regions as compared to developing regions. Similarly, according to Cancer Organization India, in 2018, breast and oral cavity cancers accounted for 25.0% of cancer cases in women. Furthermore, according to Susan G Komen Breast Cancer Foundation, Inc., in 2019, around 41,760 women are expected to die due to breast cancer.

In addition, according to the South African Journal of Radiology, in 2018, breast cancer is one of the most common types of cancer in South Africa in women and is also one of the leading causes of death. Therefore, such an increased prevalence of breast cancer is one of the key factors driving the demand for mammography devices, as they may be used for diagnostic purposes.

Furthermore, as the world's population is rising, a large proportion of women might reach the age of 60 or older. Women over the age of 60 accounts for about 78% of all breast cancer-related fatalities. Breast cancer has a high incidence and fatality rate in this age range, indicating significant unmet demand for breast cancer diagnostics. The need for mammography is likely to rise as the number of events and fatalities rises. Thus, the increasing geriatric population is expected to propel market growth over the forecast period.

The introduction of new products in the market is expected to boost the adoption rate among end users. The earlier generation of mammography systems provided 2D images of the breast, which limits the interpretation quality. 2D mammography systems provide Craniocaudal (CC) and Mediolateral-Oblique (MLO) images. The flat nature of these images makes it difficult for physicians to interpret images and identify tumors due to overlapping of tissues and calcifications, which masks cancerous lesions. With the introduction of new 3D-based technology called Digital Breast Tomosynthesis (DBT), it is possible to obtain a 3D image of the breast. This allows radiologists to scan the breast slice by slice and identify abnormalities, which would be obscured in 2D images.

Product Insights

The digital systems segment held the dominant revenue share of more than 60% in 2021 and is expected to witness considerable growth over the forecast period. Rising demand for technologically improved breast cancer screening systems is one of the main factors expected to drive the growth. Government-issued Acts, such as Medical Imaging Modernization Act, 2015, ordained to promote technological advancements, resulted in a surge of demand for the 3D system.

Furthermore, owing to its huge commercial availability and rising demand among healthcare professionals are contributing to the growth of the segment. Some of the key players operating majorly in this segment are Siemens Healthcare Private Limited and General Electric Company (GE Healthcare). In January 2019, Kiran Medical Systems, the radiology division of Trivitron Healthcare, launched a digital mammography system, Elite - Flat Panel Digital C-arm & Felicia.

The 3D systems segment is anticipated to be the fastest-growing segment with a CAGR of 12.2% over the forecast period. This is owing to several advantages, hospitals & diagnostic clinics are switching to 3D systems as 2D systems are often ineffective in detecting every sign of cancer, increasing the need for additional screenings, which, in turn, increases the overall diagnostic cost. The widespread adoption of 3D systems is owing to technological benefits such as increased breast cancer detection rates, the ability to manage bigger procedure volumes, and a more advantageous reimbursement scenario.

Furthermore, the trend of 3D mammography system leasing contract agreements is increasing. Rental contract agreements allow end-users to pay a set fee for each 3D mammogram conducted utilizing 3D mammography technology provided by manufacturers at no cost. This enables low-income hospitals and diagnostic labs to implement this cutting-edge breast imaging technology.

Additionally, in recent years, some countries have implemented public mammography screening. In these public mammography screening programs, 3D mammography devices are employed to achieve the highest level of accuracy in the identification of breast cancer. Thus, the aforementioned factors are anticipated to contribute to the segment’s rapid growth in forthcoming years.

Technology Insights

In 2021, the digital mammography technology segment accounted for the largest revenue share of more than 66.0%, owing to the various advantages of the technology. Digital mammography is a specialized and sophisticated form of mammography that examines breast tissue for the presence of cancers using digital sensors and computers rather than X-ray films.

In most countries, conventional screen-film mammography (SFM) with a high spatial resolution has been the preferred choice for screening programs. However, with the introduction of digital mammography, a growing number of countries are shifting toward these newer systems, owing to their superior depiction of low-contrast objects, wider dynamic change, and enhanced diagnostic quality of images, particularly when evaluating denser breasts.

Moreover, they also have the added benefit of soft-copy visual displays and soft-copy reading, both of which are easily transferable. Mammography screening is now digital in many nations, including the U.K., providing greater precision, higher quality, and greater efficiency. As a result, digital mammography is becoming the standard screening method, although the new equipment is six times more expensive than traditional systems.

Furthermore, in comparison to analog systems, radiation exposure is reduced significantly. The most prevalent type of digital mammography used is full-field digital mammography. It has the potential to make substantial advancements in breast cancer diagnostics, such as lowering radiation doses, reducing breast compression pressure, and improving detection. All of these benefits will contribute to the market's growth over the forecast period.

The breast tomosynthesis technology segment is expected to witness the fastest CAGR of 12.1% over the forecast period. Digital breast tomosynthesis is a high-resolution limited-angle tomography technology that uses X-rays to create a 3D image of the breast. This new technique aids early identification of breast cancer. Digital breast tomosynthesis is very useful in analyzing dense breasts and can enhance the ability to detect breast cancer. It minimizes the number of false-positive readings (readings that identify normal tissue as abnormal) and the necessity for a biopsy. It is suitable for any woman, but it is especially good for those with dense breasts.

Furthermore, several major studies have indicated that combined 2D/3D mammography systems are superior to 2D mammography alone in the diagnosis of breast cancer. A large US study of 4,54,850 patients observed that combined 2D/3D Combination screening detected 5.5 cancers per 1,000 women, compared to 4.3 cancers for 2D screening alone, a 28 percent higher detection rate with combined 2D/3D mammography systems, according to the American Society of Clinical Oncology (ASCO) clinical trial report. Thus, increasing awareness of the usage of these systems, as well as high detection rates, are the primary driving the segment growth.

Regional Insights

North America dominated the market in 2021 with a revenue share of around 41% and is expected to exhibit considerable CAGR over the forecast period. The rising incidence of breast cancer is one of the major factors driving the market growth in North America. According to the American Cancer Society, approximately 276,480 new cases of invasive breast cancer among women would be detected in 2020. Furthermore, 48,530 cases of in situ breast carcinoma in women have been discovered, and the number of breast cancer cases is predicted to rise in the forthcoming years.

Numerous companies have begun to establish initiatives to assist with breast cancer tests. For example, Hologic Inc. announced the beginning of the Back to Screening campaign in August 2020, which may motivate women to schedule their postponed mammograms due to the COVID-19 pandemic. The National Breast Cancer Foundation (NBCF) is an organization in the United States that offers breast cancer education and free mammograms to women in need. In addition, the presence of highly developed healthcare infrastructure and increasing healthcare spending are among the factors anticipated to drive the market growth.

Asia Pacific is anticipated to witness the fastest CAGR over the forecast period. The increased prevalence of breast cancer, high R&D investments in breast cancer therapies, and developments in breast imaging modalities are the primary growth drivers. Breast cancer is the most frequent malignancy in most Asian countries regardless of race or ethnicity, according to the Centers for Disease Control and Prevention (CDC).

According to GLOBOCAN 2018, the age-standardized incidence rate of breast cancer in Asia is 34.4 per 100,000 people. Thus, the increased prevalence of breast cancer and the region's expanding healthcare infrastructure are likely to fuel overall growth. The presence of developing countries, such as China, Japan, and India, is anticipated to boost the market growth. In addition, key players are making constant efforts to enter emerging markets of Asia Pacific, which is expected to boost the growth.

Key Companies & Market Share Insights

The market is consolidated, due to the presence of a few major players. The foremost market players are focusing on technological advancements and reducing the side effects of the procedures. These companies have a wide product portfolio, which includes breast tomosynthesis technology, digital mammography, computer-aided detection, and breast biopsy devices.

The market participants are actively involved in multiple strategic initiatives to maintain their position in the market. For instance, in December 2020, Hologic Inc., a developer, producer, & provider of high-quality diagnostics, and medical imaging devices announced U.S. FDA clearance for its Genius AI Detection technology, a new deep learning-based software designed to aid radiologists detect subtle potential cancers in breast tomosynthesis images. These strategies are expected to fuel the growth of the market during the forecast period.

Some prominent players in the global mammography market include:

• Hologic Inc.

• Analogic Corporation,

• Canon Medical Systems Corporation,

• Fujifilm Corporation

• Siemens Healthcare

• Toshiba Medical Systems

• GE Healthcare

• Metaltronica

• Koninklijke Philips NV

• PLANMED OY

Mammography Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global mammography market report based on product, technology, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Film Screen Systems

  • Digital Systems

  • Analog Systems

  • Biopsy Systems

  • 3D Systems

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Breast Tomosynthesis

  • CAD

  • Digital

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

  • Latin America

    • Mexico

    • Brazil

    • Argentina

    • Colombia

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE